Explore Treatments for Primary Immune Deficiency Diseases (PI) 

Primary immunodeficiency diseases (PI) are a group of over 450 rare, lifelong disorders where parts of the immune system are missing or don’t work properly. These conditions are caused by inherited genetic defects. While some are present from birth or early childhood, PI can affect anyone, regardless of age or gender. Some forms of PI affect just one part of the immune system, while others affect multiple components. Despite their differences, all PI conditions share one key feature: a defect in how the immune system normally protects the body. For people with PI, infections may not go away easily or may return frequently, even with treatment. These infections can be common, severe, long-lasting, difficult to cure, and sometimes life-threatening.

Treatments Offered by CSI

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma is rigorously processed and purified to ensure product safety and integrity. Intravenous immunoglobulin (IVIG) contains antibodies that provide broad protection against a wide range of bacteria and viruses. It is administered intravenously and is primarily used to treat three categories of conditions: primary immunodeficiency diseases, autoimmune disorders, and certain neurological conditions. 

  • Alyglo 10% 
  • Asceniv 10% 
  • Bivigam 10% 
  • Gammagard S/D 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Gammaplex 5% 
  • Gammaplex 10% 
  • Octagam 5% 
  • Octagam 10% 
  • Panzyga 10% 
  • Privigen 10% 
  • Yimmugo 10% 

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma undergoes rigorous processing and purification to ensure the highest standards of safety and product integrity. Subcutaneous immunoglobulin (SCIG) contains antibodies that offer broad protection against a wide range of bacteria and viruses. It is administered under the skin (subcutaneously) and is primarily used to treat primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy (CIDP). SCIG is also being studied in clinical trials for use in additional conditions. 

  • Cutaquig 16.5%  
  • Cuvitru 20% 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Hizentra 20% 
  • HyQvia 10% (facilitated SCIG)  
  • Xembify 20%